These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31982514)

  • 1. Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals.
    Beck KR; Telisman L; van Koppen CJ; Thompson GR; Odermatt A
    J Steroid Biochem Mol Biol; 2020 May; 199():105605. PubMed ID: 31982514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole.
    Beck KR; Bächler M; Vuorinen A; Wagner S; Akram M; Griesser U; Temml V; Klusonova P; Yamaguchi H; Schuster D; Odermatt A
    Biochem Pharmacol; 2017 Apr; 130():93-103. PubMed ID: 28131847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species-specific differences in the inhibition of 11β-hydroxysteroid dehydrogenase 2 by itraconazole and posaconazole.
    Inderbinen SG; Zogg M; Kley M; Smieško M; Odermatt A
    Toxicol Appl Pharmacol; 2021 Feb; 412():115387. PubMed ID: 33387577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posaconazole-Induced Pseudohyperaldosteronism.
    Kuriakose K; Nesbitt WJ; Greene M; Harris B
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess.
    Beck KR; Odermatt A
    Mol Cell Endocrinol; 2021 Mar; 524():111168. PubMed ID: 33484741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the potential risk of oteseconazole and two other tetrazole antifungals to inhibit adrenal steroidogenesis and peripheral metabolism of corticosteroids.
    Jäger MC; González-Ruiz V; Joos FL; Winter DV; Boccard J; Degenhardt T; Brand S; Rudaz S; Thompson GR; Odermatt A
    Front Pharmacol; 2024; 15():1394846. PubMed ID: 39175536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays.
    Jäger MC; Joos FL; Winter DV; Odermatt A
    Curr Res Toxicol; 2023; 5():100119. PubMed ID: 37637492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation.
    Hoffmann WJ; McHardy I; Thompson GR
    Mycoses; 2018 May; 61(5):337-339. PubMed ID: 29385285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biology of 11β-hydroxylase and 11β-hydroxysteroid dehydrogenase enzymes.
    White PC; Pascoe L; Curnow KM; Tannin G; Rösler A
    J Steroid Biochem Mol Biol; 1992 Dec; 43(8):827-35. PubMed ID: 22217826
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Thompson GR; Chang D; Wittenberg RR; McHardy I; Semrad A
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro methods to assess 11β-hydroxysteroid dehydrogenase type 2 activity.
    Kley M; Moser SO; Winter DV; Odermatt A
    Methods Enzymol; 2023; 689():167-200. PubMed ID: 37802570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional effects of genetic variants in the 11beta-hydroxylase (CYP11B1) gene.
    Barr M; MacKenzie SM; Wilkinson DM; Holloway CD; Friel EC; Miller S; MacDonald T; Fraser R; Connell JM; Davies E
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):816-25. PubMed ID: 17121536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal Therapy with Azoles Induced the Syndrome of Acquired Apparent Mineralocorticoid Excess: a Literature and Database Analysis.
    Ji HH; Tang XW; Zhang N; Huo BN; Liu Y; Song L; Jia YT
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0166821. PubMed ID: 34662186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
    Sanglard D; Coste AT
    Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid hypertension and hypokalaemia induced by posaconazole.
    Boughton C; Taylor D; Ghataore L; Taylor N; Whitelaw BC
    Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29472988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state.
    Li A; Li KX; Marui S; Krozowski ZS; Batista MC; Whorwood CB; Arnhold IJ; Shackleton CH; Mendonca BB; Stewart PM
    J Hypertens; 1997 Dec; 15(12 Pt 1):1397-402. PubMed ID: 9431844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posaconazole-Induced Hypertension Due to Inhibition of 11
    Thompson GR; Beck KR; Patt M; Kratschmar DV; Odermatt A
    J Endocr Soc; 2019 Jul; 3(7):1361-1366. PubMed ID: 31286100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol.
    Mulatero P; Curnow KM; Aupetit-Faisant B; Foekling M; Gomez-Sanchez C; Veglio F; Jeunemaitre X; Corvol P; Pascoe L
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3996-4001. PubMed ID: 9814482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual screening and biological evaluation to identify pharmaceuticals potentially causing hypertension and hypokalemia by inhibiting steroid 11β-hydroxylase.
    Jäger MC; Kędzierski J; Gell V; Wey T; Kollár J; Winter DV; Schuster D; Smieško M; Odermatt A
    Toxicol Appl Pharmacol; 2023 Sep; 475():116638. PubMed ID: 37499767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apparent Mineralocorticoid Excess in the Pediatric Population: Report of a Novel Pathogenic Variant of the 11β-HSD2 Gene and Systematic Review of the Literature.
    Adamidis A; Cantas-Orsdemir S; Tsirka A; Abbott MA; Visintainer P; Tonyushkina K
    Pediatr Endocrinol Rev; 2019 Mar; 16(3):335-358. PubMed ID: 30888125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.